Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

It is known that VIP has various effects on intestinal functions: i) it is a potent stimulant of mucosal water and electrolyte secretion: ii) it is involved in the peristaltic reflex: and iii) plays an inhibitory role on immune cell function. Based on these biological effects it has been hypothesized that the intestinal mucosal immune system and inflammation may be influenced by alterations in the tissue concentrations of VIP. Some authors have demonstrated no changes in the VIP colonic content of patients with ulcerative colitis [UC], whereas others have demonstrated a reduction. Our results, using specific radioimmunoassay, showed that there is a significant decrease of VIP in both rectal and colonic mucosa of patients with ulcerative colitis [UC] as compared to controls. The VIP decrease is selective since substance P and calcitonin gene-related peptide were unchanged in the mucosal tissue of ulcerative colitis patients and furthermore the VIP alteration is correlated to the degree of mucosal inflammation. These findings suggest that the reduction of VIP mucosal content, even if it represents a non-specific event, could influence local inflammatory response and the activity of the disease.

https://www.sciencedirect.com/science/article/abs/pii/092842579390037T

The treatment of UC includes traditional therapies such as drugs made of tumor necrosis factor (TNF) inhibitors and small molecule. The global ulcerative colitis market accounted for $4,785 million in 2016 and is expected to reach $7,455 million by 2023, registering a CAGR of 6.5% from 2017 to 2023.

https://www.alliedmarketresearch.com/ulcerative-colitis-market